SHBG Sex- and Cycle-Related Differences: Normal Ranges, Optimal Levels, and Clinical Interpretation

What Is SHBG and Why Does It Matter?

Sex hormone-binding globulin is a glycoprotein synthesized primarily in the liver. It binds testosterone with roughly three times the affinity it binds estradiol, and it binds dihydrotestosterone (DHT) with even greater avidity than testosterone. Because only the unbound ("free") fraction of a steroid hormone can enter target cells and activate nuclear receptors, SHBG is not a passive bystander: it is the gatekeeper that determines how much biologically active hormone reaches tissue.

Total testosterone can appear normal while free testosterone is critically low if SHBG is elevated. The reverse is also true: a man with low-normal total testosterone but suppressed SHBG may have adequate free testosterone. Neither reading makes clinical sense without the other.

SHBG Structure and Binding Mechanics

SHBG is a homodimer. Each monomer contains one steroid-binding site, and the protein circulates at nanomolar concentrations, far below the micromolar concentrations of cortisol-binding globulin. Because its binding capacity is limited, small shifts in production rate produce outsized changes in free hormone fractions. A 20 nmol/L rise in SHBG in a man with total testosterone of 500 ng/dL can reduce free testosterone by 15 to 25%, enough to cause symptomatic androgen deficiency without any change in testicular output. SHBG physiology is reviewed in detail at the National Library of Medicine.

How SHBG Is Measured

Most clinical laboratories measure SHBG by immunoassay. Results are reported in nmol/L (SI units) or, less commonly, in mcg/dL. Reference ranges differ between assay platforms; a result of 35 nmol/L on one analyzer may not map exactly to a result of 35 nmol/L on another. Always interpret SHBG against the same laboratory's reference interval, and retest on the same platform when tracking trends over time.

SHBG Normal Ranges by Sex

Men

In adult men, SHBG typically runs between 10 and 57 nmol/L, with a population median near 30 to 35 nmol/L in men aged 20 to 40. The Third National Health and Nutrition Examination Survey (NHANES III) established sex-specific reference data showing that male SHBG is substantially lower than female SHBG across all adult age groups. This reflects the chronic suppressive effect of endogenous testosterone on hepatic SHBG production.

Low SHBG in men is common with obesity, type 2 diabetes, and insulin resistance. High SHBG in men is seen with aging, hyperthyroidism, hepatic disease, and antiandrogen therapy.

Women

Women of reproductive age show a wider and higher reference range, typically 18 to 144 nmol/L, because estradiol stimulates hepatic SHBG synthesis while progesterone has a modest suppressive effect. This broader range reflects the physiological reality that SHBG is not static: it moves across the menstrual cycle, across pregnancy, and across the menopausal transition.

Postmenopausal women not using hormone therapy generally show SHBG values closer to the male range (20 to 60 nmol/L), driven by the fall in endogenous estradiol. Women using oral estrogen-containing hormone therapy or oral contraceptives may see SHBG climb to 200 to 400 nmol/L, which has direct consequences for free androgen availability.

A 2005 study in the Journal of Clinical Endocrinology and Metabolism (N=699 women) confirmed that SHBG in premenopausal women is roughly two to three times higher than in age-matched men, largely because of the differential effect of sex steroids on liver SHBG gene expression. (PMID 15522942)

SHBG Changes Across the Menstrual Cycle

SHBG is not constant across the 28-day cycle. It rises during the follicular phase, peaks in the periovulatory window, and falls modestly in the luteal phase as progesterone concentrations climb.

Follicular Phase (Days 1 to 13)

Rising estradiol during the follicular phase drives hepatic SHBG synthesis upward. By the late follicular phase, SHBG may be 15 to 30% higher than early-cycle values in the same woman. This rise effectively attenuates the bioavailability of the androgen surge that accompanies the LH surge, an arrangement that may have reproductive significance by preventing excessive androgenic stimulation of follicular granulosa cells.

Periovulatory Peak (Day 14, Approximately)

The LH surge and peak estradiol at midcycle coincide with the highest SHBG values of the cycle. Free testosterone at this point is paradoxically elevated despite high SHBG, because the absolute estradiol-driven testosterone rise outpaces the SHBG rise. This transient increase in free testosterone near ovulation has been linked to the midcycle increase in female libido documented in observational cohort data. (PMID 2757178)

Luteal Phase (Days 15 to 28)

After ovulation, progesterone from the corpus luteum competes weakly with testosterone for SHBG binding and may reduce SHBG synthesis modestly. SHBG falls 10 to 20% from its periovulatory peak. Free testosterone rises proportionally. Women who report premenstrual acne or mood symptoms in the luteal phase often show the combined effect of falling SHBG and rising androgen bioavailability during this window.

Practical Implication for Lab Timing

Testing SHBG and total testosterone in women should be done consistently in the early follicular phase (days 2 to 5) to allow serial comparisons. A result drawn on day 14 versus day 3 can differ by 25% or more in the same woman with no pathological change. The Endocrine Society's 2014 guideline on androgen deficiency in women recommends early-follicular phase testing for this reason.

SHBG Across the Female Lifespan

SHBG is not a single number. It shifts across decades, reflecting the hormonal milieu of each life stage.

Adolescence

Pubertal SHBG in girls starts high and declines as ovarian estradiol production rises and body fat increases. By age 16 to 18, SHBG settles into the adult female range.

Reproductive Years

SHBG during the reproductive years is regulated primarily by estradiol, body composition, and insulin sensitivity. Women with polycystic ovary syndrome (PCOS) typically show SHBG values below 50 nmol/L due to hyperinsulinemia suppressing hepatic SHBG output. The Rotterdam criteria for PCOS include androgen excess, and low SHBG is both a marker and a mechanism: low SHBG raises free androgen, worsening the androgenic phenotype.

Perimenopause and Menopause

The menopausal transition brings falling estradiol and therefore falling SHBG. Most postmenopausal women without HRT show SHBG in the range of 25 to 65 nmol/L. This fall in SHBG paradoxically increases free testosterone even as total testosterone falls with aging, which partly explains why postmenopausal women do not always report the degree of androgen deficiency that their low total testosterone figures would predict.

Pregnancy

Pregnancy drives the most dramatic SHBG surge across the female lifespan. By the third trimester, SHBG concentrations may reach 300 to 1,000 nmol/L, driven by placentally derived estrogens. This rise is physiologically important: it limits free steroid availability to both mother and fetus during a period of surging hormone production.

SHBG Across the Male Lifespan

Men show a slow but consistent rise in SHBG with aging. Testosterone begins declining at approximately 1 to 2% per year after age 30. SHBG rises at roughly 1 to 2% per year after age 40. The combined effect is that free testosterone falls faster than total testosterone, meaning that a man whose total testosterone is "normal" at age 60 may have free testosterone equivalent to a hypogonadal younger man.

Age 20 to 40

Median SHBG sits near 25 to 35 nmol/L. Low SHBG in this age group is almost always metabolic, driven by obesity, insulin resistance, or anabolic steroid use.

Age 40 to 60

SHBG creeps upward. Mean values in population studies reach 35 to 45 nmol/L. Free testosterone declines faster than total testosterone. The Massachusetts Male Aging Study found that free testosterone fell at approximately 2.5% per year in men aged 40 to 70, compared with 1.6% per year for total testosterone, a difference explained in large part by the concurrent SHBG rise.

Age 60 and Above

SHBG commonly exceeds 50 nmol/L. Several population studies have found mean SHBG of 55 to 70 nmol/L in men over 70. At these concentrations, even a total testosterone in the low-normal range (300 to 350 ng/dL) can be associated with free testosterone below 50 pg/mL, well below the threshold associated with symptomatic hypogonadism in most laboratory reference systems.

What Raises and Lowers SHBG

Understanding the drivers of SHBG is as useful clinically as knowing the number itself.

Factors That Raise SHBG

Estrogens are the strongest stimulator of hepatic SHBG gene transcription. Oral estradiol raises SHBG more than transdermal estradiol because the first-pass hepatic effect amplifies SHBG synthesis. A woman switching from a 0.1 mg estradiol patch to an oral estradiol 2 mg tablet may see SHBG double. Ethinyl estradiol in combined oral contraceptives raises SHBG even more dramatically, sometimes to 200 to 400 nmol/L, suppressing free testosterone and explaining some of the libido complaints associated with oral contraceptives documented by Panzer et al. In The Journal of Sexual Medicine (2006). (PMID 16422843)

Thyroid hormone increases SHBG transcription. Hyperthyroidism raises SHBG; hypothyroidism lowers it. Liver disease (hepatitis, cirrhosis) raises SHBG through impaired clearance. Aging raises SHBG in men through mechanisms that are not fully characterized but likely involve reduced androgen-driven suppression as testosterone declines.

Factors That Lower SHBG

Androgens suppress hepatic SHBG synthesis. Exogenous testosterone, whether injectable, topical, or oral, lowers SHBG within days to weeks. Insulin suppresses SHBG production: every 10-unit increase in fasting insulin may reduce SHBG by 10 to 15%. (PMID 10084567)

Obesity lowers SHBG through the hyperinsulinemia mechanism, not through adipose tissue effects on SHBG directly. Losing 10% of body weight can raise SHBG by 10 to 20 nmol/L in obese individuals, which in turn reduces free androgen and may help break the hyperandrogenism cycle in PCOS. Hypothyroidism, glucocorticoids, and anabolic steroids all suppress SHBG.

Optimal SHBG: What the Evidence Supports

"Normal" and "optimal" are not the same value. Reference ranges are derived from population distributions; optimal ranges are derived from outcome data.

Optimal SHBG in Men

The longevity-medicine and men's health consensus, supported by data from the European Male Ageing Study (EMAS) and the Framingham Heart Study offspring cohort, places optimal SHBG for adult men at 20 to 40 nmol/L. Below 20 nmol/L, men show higher rates of type 2 diabetes, metabolic syndrome, and cardiovascular risk markers. Above 40 to 50 nmol/L, free testosterone begins falling into ranges associated with hypogonadal symptoms even when total testosterone appears normal.

The European Male Ageing Study (N=3,369 men aged 40 to 79) found that SHBG above 50 nmol/L was independently associated with sexual dysfunction symptoms after adjusting for total testosterone, confirming that SHBG carries independent clinical weight beyond its role in free-T calculation.

The American Urological Association's 2018 guideline on testosterone deficiency states: "Calculated free testosterone using the Vermeulen equation, incorporating SHBG and albumin, is the preferred method for assessing androgen status when total testosterone is in the borderline range (200 to 400 ng/dL)." (AUA guideline, referenced at endocrine.org)

Optimal SHBG in Women

For reproductive-age women, SHBG in the range of 40 to 120 nmol/L (early follicular phase) supports normal ovarian function and androgen bioavailability. SHBG below 30 nmol/L in a woman of reproductive age warrants investigation for hyperinsulinemia, PCOS, or exogenous androgen exposure.

Postmenopausal women not using hormone therapy: SHBG of 25 to 60 nmol/L is typical and consistent with preserved free testosterone adequate for libido and muscle maintenance.

Women using oral combined hormone therapy or oral contraceptives with SHBG consistently above 150 nmol/L may have free testosterone so suppressed (<0.5 pg/mL free T by equilibrium dialysis) that androgen-dependent symptoms, including reduced libido and blunted orgasm, may emerge. Switching to a transdermal estrogen delivery route that avoids first-pass hepatic stimulation is a standard clinical intervention in this scenario.

Calculating Free Testosterone from SHBG

The Vermeulen equation (also called the Sodergard equation in some literature) uses total testosterone, SHBG, and albumin (assumed at 4.3 g/dL unless measured) to compute free testosterone. Most clinical labs offer this as a calculated value. Online calculators are available at ISSAM's free testosterone calculator.

The formula matters because direct immunoassay for free testosterone is notoriously unreliable at low concentrations, with inter-assay coefficients of variation sometimes exceeding 20 to 30%. Equilibrium dialysis is the reference method for free testosterone but is expensive and rarely available clinically. The Vermeulen calculation on a quality SHBG immunoassay is a practical compromise endorsed by both the Endocrine Society and the European Association of Urology.

Free testosterone thresholds used clinically:

• Men: free testosterone <50 pg/mL (by calculation) consistent with symptomatic hypogonadism in most systems; some guidelines use <65 pg/mL as the lower normal limit.
• Women: free testosterone <0.5 to 1.0 pg/mL by equilibrium dialysis associated with androgen insufficiency; calculated free T thresholds are less well validated in women.

SHBG in Hormone Therapy Monitoring

Testosterone Replacement Therapy (TRT) in Men

Exogenous testosterone suppresses SHBG, typically by 20 to 40% from baseline within 4 to 8 weeks of initiating therapy. This SHBG suppression partially offsets the total testosterone rise, meaning that the increase in free testosterone is proportionally larger than the increase in total testosterone. Clinicians who track only total testosterone during TRT may underestimate bioavailable androgen delivery. Checking SHBG at baseline and at 6 to 12 weeks on a stable dose provides a more complete picture.

Injectable testosterone cypionate or enanthate, dosed every 7 to 14 days, produces greater SHBG suppression than daily transdermal formulations because peak androgen exposure is higher. (PMID 12788990)

Hormone Replacement Therapy (HRT) in Women

Route of estrogen delivery is the dominant determinant of SHBG response in menopausal HRT. Oral estradiol at 1 to 2 mg/day raises SHBG by 50 to 100% above baseline. Transdermal estradiol at equivalent doses raises SHBG by only 10 to 20% or less. This pharmacokinetic difference has clinical consequences for women with baseline low libido or reduced free testosterone: transdermal HRT is preferred when androgen bioavailability needs to be preserved. The KEEPS trial (Kronos Early Estrogen Prevention Study) demonstrated this route-dependent SHBG differential in randomized comparison of oral conjugated equine estrogen versus transdermal estradiol.

Women adding testosterone therapy (off-label in the U.S., approved in the UK as Testavan or Androfeme) should have SHBG checked before initiation: women with SHBG above 100 nmol/L may require higher testosterone doses to achieve equivalent free testosterone targets, since more of the dosed testosterone will be immediately bound.

SHBG as a Metabolic Marker

Beyond its role as a carrier protein, SHBG is an independent predictor of metabolic disease risk.

SHBG and Diabetes Risk

A meta-analysis published in Diabetes Care (2010) covering 11 prospective studies and more than 15,000 participants found that each doubling of SHBG concentration was associated with a 69% lower risk of type 2 diabetes in women (RR 0.31, 95% CI 0.24 to 0.41) and a 52% lower risk in men. (PMID 20040655) Low SHBG is now considered a metabolic risk marker in its own right, not merely a downstream consequence of hyperinsulinemia.

SHBG and Cardiovascular Disease

The Framingham Offspring Study found that low SHBG in men was associated with increased odds of metabolic syndrome independent of total testosterone. Men in the lowest SHBG quartile had a 2.1-fold higher prevalence of metabolic syndrome compared with those in the highest quartile. (PMID 17644752)